Patent ID: 8920808

Claim:
A method of treating multiple sclerosis comprising administering to a subject an effective amount of a first and at least a second fusion protein, wherein the first and the at least second fusion protein each independently comprise: (a) an encephalitogenic determinant of an autoimmune antigen selected from the group consisting of myelin basic protein (MBP), proteolipid protein (PLP), myelin oligodendrocyte glycoprotein (MOG) and myelin-associated oligodendrocytic basic protein; and (b) an anti-inflammatory cytokine selected from the group consisting of an interleukin or interleukin receptor antagonist, wherein the anti-inflammatory cytokine of the first fusion protein is interleukin-2 (IL-2) and the anti-inflammatory cytokine of the at least second fusion protein is interleukin-4 (IL-4), interleukin-10 (IL-10), interleukin-13 (IL-13), interleukin-16 (IL-16), interferon-beta (IFN-β) or transforming growth factor-beta (TGF-β) and the interleukin receptor antagonist is interleukin-1RA (IL-1RA).